Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/621
Título : Extracellular tumor-related mRNA in plasma of lymphoma patients and survival implications.
Autor : García, Vanesa
García, José Miguel
Silva, Javier
Martín, Paloma
Peña, Cristina
Domínguez, Gemma
Díaz, Raquel
Herrera, Mercedes
Maximiano, Constanza
Sabin, Pilar
Rueda Domínguez, Antonio
Cruz, Miguel Ángel
Rodríguez, José
Canales, Miguel Ángel
Bonilla, Félix
Provencio, Mariano
Filiación: [García,V; García,JM; Silva,J; Peña,C; Dominguez,G; Díaz,R; Herrera,M; Constanza,M; Bonilla,F; Provencio,M] Department of Medical Oncology, Puerta de Hierro University Hospital, Madrid, Spain. [Martín,P] Department of Molecular Pathology, Puerta de Hierro University Hospital, Madrid, Spain. [Sabin,P; Rodríguez,J] Department of Medical Oncology, Gregorio Marañón Hospital, Madrid, Spain. [Rueda Domínguez,A] Department of Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain. [Cruz,MA] Department of Medical Oncology, Virgen de la Salud Hospital, Toledo, Spain. [Canales,MA] Department of Hematology, La Paz Hospital, Madrid, Spain.
Palabras clave : Espacio Extracelular
Inmunohistoquímica
Estimación de Kaplan-Meier
Linfoma de Células B Grandes Difuso
Células Neoplásicas Circulantes
ARN Mensajero
ARN Neoplásico
Factores de riesgo
Supervivencia sin Enfermedad
MeSH: Medical Subject Headings::Anatomy::Tissues::Body Fluid Compartments::Extracellular Space
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Cytological Techniques::Histocytochemistry::Immunohistochemistry
Medical Subject Headings::Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Statistics as Topic::Survival Analysis::Kaplan-Meier Estimate
Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse
Medical Subject Headings::Anatomy::Cells::Neoplastic Cells, Circulating
Medical Subject Headings::Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::RNA::RNA, Messenger
Medical Subject Headings::Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::RNA::RNA, Neoplasm
Medical Subject Headings::Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Epidemiologic Factors::Causality::Risk Factors
Medical Subject Headings::Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Statistics as Topic::Survival Analysis::Disease-Free Survival
Fecha de publicación : 15-Dec-2009
Editorial : Public Library of Science
Cita Bibliográfica: García V, García JM, Silva J, Martín P, Peña C, Domínguez G, et al. Extracellular tumor-related mRNA in plasma of lymphoma patients and survival implications. PLoS ONE; 4(12):e8173
Abstract: BACKGROUND We studied anomalous extracellular mRNAs in plasma from patients with diffuse large B-cell lymphoma (DLBCL) and their survival implications. mRNAs studied have been reported in the literature as markers of poor (BCL2, CCND2, MYC) and favorable outcome (LMO2, BCL6, FN1) in tumors. These markers were also analyzed in lymphoma tissues to test possible associations with their presence in plasma. METHODOLOGY/PRINCIPAL FINDINGS mRNA from 42 plasma samples and 12 tumors from patients with DLBCL was analyzed by real-time PCR. Samples post-treatment were studied. The immunohistochemistry of BCL2 and BCL6 was defined. Presence of circulating tumor cells was determined by analyzing the clonality of the immunoglobulin heavy-chain genes by PCR. In DLBCL, MYC mRNA was associated with short overall survival. mRNA targets with unfavorable outcome in tumors were associated with characteristics indicative of poor prognosis, with partial treatment response and with short progression-free survival in patients with complete response. In patients with low IPI score, unfavorable mRNA targets were related to shorter overall survival, partial response, high LDH levels and death. mRNA disappeared in post-treatment samples of patients with complete response, and persisted in those with partial response or death. No associations were found between circulating tumor cells and plasma mRNA. Absence of BCL6 protein in tumors was associated with presence of unfavorable plasma mRNA. CONCLUSIONS/SIGNIFICANCE Through a non-invasive procedure, tumor-derived mRNAs can be obtained in plasma. mRNA detected in plasma did not proceed from circulating tumor cells. In our study, unfavorable targets in plasma were associated with poor prognosis in B-cell lymphomas, mainly MYC mRNA. Moreover, the unfavorable targets in plasma could help us to classify patients with poor outcome within the good prognosis group according to IPI.
Descripción : Journal Article; Research Support, Non-U.S. Gov't;
URI: http://hdl.handle.net/10668/621
Versión del editor : http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0008173
DOI: 10.1371/journal.pone.0008173
ISSN : 1932-6203 (Online)
Appears in Collections:01- Artículos - Hospital Virgen de la Victoria

Files in This Item:
File Description SizeFormat 
Garcia_Extracellular.pdfArtículo publicado2,41 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons